Starpharma Holdings Limited (ASX:SPL) Insider Robert Thomas Purchases 200,000 Shares

Starpharma Holdings Limited (ASX:SPL) insider Robert Thomas acquired 200,000 shares of the stock in a transaction on Wednesday, June 26th. The stock was bought at an average price of A$0.09 ($0.06) per share, with a total value of A$17,800.00 ($11,866.67).

Robert Thomas also recently made the following trade(s):

• On Thursday, June 20th, Robert Thomas purchased 250,000 shares of Starpharma stock. The stock was purchased at an average cost of A$0.09 ($0.06) per share, for a total transaction of A$22,750.00 ($15,166.67).
• On Wednesday, May 29th, Robert Thomas purchased 150,000 shares of Starpharma stock. The shares were acquired at an average price of A$0.12 ($0.08) per share, for a total transaction of A$17,700.00 ($11,800.00).
• On Wednesday, April 10th, Robert Thomas acquired 250,000 shares of Starpharma stock. The stock was acquired at an average price of A$0.17 ($0.12) per share, with a total value of A$43,500.00 ($29,000.00).
• On Monday, April 15th, Robert Thomas bought 100,000 shares of Starpharma stock. The shares were acquired at an average price of A$0.13 ($0.09) per share, with a total value of A$13,000.00 ($8,666.67).

Starpharma Price Performance

The company has a debt-to-equity ratio of 9.08, a current ratio of 5.60 and a quick ratio of 5.65.

About Starpharma

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.